Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy - PubMed (original) (raw)
Clinical Trial
Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy
D Zagury et al. Biomed Pharmacother. 1999 Mar.
Abstract
HAART (highly active antiretroviral therapy) suppresses but does not eradicate HIV-1 infection. However, since the antiretroviral agents used in HAART may also be toxic in the long-term, immunotherapies which correct HIV-1 immunosuppression or the cytokine dysregulation associated with it may be beneficial. In this respect, a double blind multicentric placebo-controlled phase II/III anti-IFN alpha vaccine trial has been carried out on 242 HIV-1 patients, the majority of whom were undergoing HAART treatment. In vaccinated patients (vaccinees) who responded to immunization by increased levels of IFN alpha Abs (whether under HAART or not) when compared to placebo or non-responder vaccinees, a strong correlation was found between an increased IFN alpha neutralizing capacity and the reduction of clinical manifestations.
Similar articles
- Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study).
Gringeri A, Musicco M, Hermans P, Bentwich Z, Cusini M, Bergamasco A, Santagostino E, Burny A, Bizzini B, Zagury D. Gringeri A, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 1;20(4):358-70. doi: 10.1097/00042560-199904010-00006. J Acquir Immune Defic Syndr Hum Retrovirol. 1999. PMID: 10096580 Clinical Trial. - IFN alpha kinoid vaccine in conjunction with tritherapy, a weapon to combat immunopathogenesis in AIDS.
Bizzini B, Volpato I, Lachgar A, Cohen P, Gringeri A. Bizzini B, et al. Biomed Pharmacother. 1999 Mar;53(2):87-9. doi: 10.1016/s0753-3322(99)80064-x. Biomed Pharmacother. 1999. PMID: 10337462 Review. - A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization.
Gringeri A, Santagostino E, Mannucci PM, Tradati F, Cultraro D, Buzzi A, Criscuolo M, David A, Guillemot L, Barré-Sinoussi F, et al. Gringeri A, et al. J Acquir Immune Defic Syndr (1988). 1994 Sep;7(9):978-88. J Acquir Immune Defic Syndr (1988). 1994. PMID: 7914235 Clinical Trial. - Anti-alpha interferon immunization: safety and immunogenicity in asymptomatic HIV positive patients at high risk of disease progression.
Gringeri A, Santagostino E, Mannucci PM, Siracusano L, Marinoni A, Criscuolo M, Carcagno M, Fall LS, M'Bika JP, Bizzini B, et al. Gringeri A, et al. Cell Mol Biol (Noisy-le-grand). 1995 May;41(3):381-7. Cell Mol Biol (Noisy-le-grand). 1995. PMID: 7580831 Clinical Trial. - Immunotherapy and therapeutic vaccines in HIV infection.
García F, Ruiz L, López-Bernaldo de Quirós JC, Moreno S, Domingo P. García F, et al. Enferm Infecc Microbiol Clin. 2005 Jul;23 Suppl 2:84-104. Enferm Infecc Microbiol Clin. 2005. PMID: 16373008 Review. English, Spanish.
Cited by
- Cognitive consequences of a sustained monocyte type 1 IFN response in HIV-1 infection.
Pulliam L. Pulliam L. Curr HIV Res. 2014;12(2):77-84. doi: 10.2174/1570162x12666140526113544. Curr HIV Res. 2014. PMID: 24862334 Free PMC article. Review. - Attenuation of CCl4-induced hepatic fibrosis in mice by vaccinating against TGF-β1.
Fan X, Zhang Q, Li S, Lv Y, Su H, Jiang H, Hao Z. Fan X, et al. PLoS One. 2013 Dec 11;8(12):e82190. doi: 10.1371/journal.pone.0082190. eCollection 2013. PLoS One. 2013. PMID: 24349218 Free PMC article. - Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells.
Goujon C, Malim MH. Goujon C, et al. J Virol. 2010 Sep;84(18):9254-66. doi: 10.1128/JVI.00854-10. Epub 2010 Jul 7. J Virol. 2010. PMID: 20610724 Free PMC article. - Interferon-alpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection.
Rempel H, Sun B, Calosing C, Pillai SK, Pulliam L. Rempel H, et al. AIDS. 2010 Jun 19;24(10):1415-23. doi: 10.1097/QAD.0b013e32833ac623. AIDS. 2010. PMID: 20495440 Free PMC article. - Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand.
Chehimi J, Papasavvas E, Tomescu C, Gekonge B, Abdulhaqq S, Raymond A, Hancock A, Vinekar K, Carty C, Reynolds G, Pistilli M, Mounzer K, Kostman J, Montaner LJ. Chehimi J, et al. J Virol. 2010 Mar;84(6):2762-73. doi: 10.1128/JVI.01350-09. Epub 2009 Dec 30. J Virol. 2010. PMID: 20042498 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical